- Home
- TSI vs TKNO Comparison
TSI vs TKNO Comparison
Compare TSI & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- TKNO
- Stock Information
- Founded
- TSI 1987
- TKNO 1996
- Country
- TSI United States
- TKNO United States
- Employees
- TSI N/A
- TKNO N/A
- Industry
- TSI Investment Managers
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- TSI Finance
- TKNO Health Care
- Exchange
- TSI Nasdaq
- TKNO Nasdaq
- Market Cap
- TSI 244.7M
- TKNO 244.7M
- IPO Year
- TSI N/A
- TKNO 2021
- Fundamental
- Price
- TSI $5.12
- TKNO $5.45
- Analyst Decision
- TSI
- TKNO Buy
- Analyst Count
- TSI 0
- TKNO 2
- Target Price
- TSI N/A
- TKNO $5.00
- AVG Volume (30 Days)
- TSI 106.8K
- TKNO 122.3K
- Earning Date
- TSI 01-01-0001
- TKNO 11-07-2024
- Dividend Yield
- TSI 7.46%
- TKNO N/A
- EPS Growth
- TSI N/A
- TKNO N/A
- EPS
- TSI N/A
- TKNO N/A
- Revenue
- TSI N/A
- TKNO $34,940,000.00
- Revenue This Year
- TSI N/A
- TKNO $3.22
- Revenue Next Year
- TSI N/A
- TKNO $14.88
- P/E Ratio
- TSI N/A
- TKNO N/A
- Revenue Growth
- TSI N/A
- TKNO N/A
- 52 Week Low
- TSI $4.48
- TKNO $1.16
- 52 Week High
- TSI $4.87
- TKNO $5.47
- Technical
- Relative Strength Index (RSI)
- TSI 55.85
- TKNO 62.45
- Support Level
- TSI $5.05
- TKNO $4.76
- Resistance Level
- TSI $5.10
- TKNO $5.07
- Average True Range (ATR)
- TSI 0.06
- TKNO 0.36
- MACD
- TSI -0.01
- TKNO 0.02
- Stochastic Oscillator
- TSI 75.00
- TKNO 98.27
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.